# IMNN-201

Source: https://onco.cc/drugs/imnn-201/  
OnCo record `imnn-201` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

IMNN-201 is an experimental DNA plasmid cancer vaccine from Imunon, in preclinical development for melanoma.

## Summary

IMNN-201 is a DNA plasmid cancer vaccine (FixPlas platform) from Imunon. A plasmid DNA vaccine against the tumour-associated antigen Trp2. Its furthest stage is preclinical development, for melanoma. No clinical trial naming it is registered on ClinicalTrials.gov. It has not been shown to work in people.

## Fields

- Kind: Treatment
- Status: preclinical
- Last checked: 2026-11-03
- Tags: pipeline
- Code: IMNN-201
- Modality: DNA plasmid cancer vaccine (FixPlas platform)
- Mechanism: A plasmid DNA vaccine against the tumour-associated antigen Trp2.

## Sources

- Imunon: imunon.com: https://imunon.com/pipeline/

## Connected records

- companies: [Imunon](https://onco.cc/companies/imunon/)

---
JSON: https://onco.cc/api/v1/entities/imnn-201.json